IZI. I. Zakirov

I. I. Zakirov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. I. Zakirov has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interferon alpha-2b with antioxidants in combination therapy for community-acquired pneumonia in children: results of a randomized study

    by A. I. Safina, I. I. Zakirov, A. R. Nazarova, M. M. Sadykov

    A prospective, open-label, randomized study was conducted to evaluate the efficiency of inclusion of recombinant interferon α-2b with vitamins C and E (Viferon®) in combination therapy for community-acquired pneumonia in children. Objective : To evaluate the efficacy and safety of interferon α-2b with antioxidants (Viferon® rectal suppositories and gel for topical use) as part of combination therapy for community-acquired pneumonia in children aged 1 to 17 years. The study was conducted in two parallel groups in November—December 2024: the main group (n = 76) received Viferon® plus standard therapy for community-acquired pneumonia according to the 2025 clinical guidelines of the Ministry of Health of the Russian Federation for 7—10 days; the comparison group (n = 65) received standard therapy alone for 7—10 days. A total of 141 children were randomized and allocated to two age strata: stratum I, children aged 1 to 7 years (n = 35; 15 in the main group and 20 in the comparison group), and stratum II, children aged 8 to 17 years (n = 106; 61 and 45 children, respectively). Study results : In 2024, community-acquired pneumonia of mycoplasma etiology was recorded in 55% of cases and was accompanied by viral co-infection in 21% of cases (influenza A/B — 7%; SARS-CoV-2 — 14%). Clinically, community-acquired pneumonia most often had a focal-confluent pattern, was accompanied by fever ≥ 38 °C, and in most cases occurred without signs of respiratory failure, while broncho-obstructive syndrome was observed in every third child. Inclusion of Viferon® in combination therapy was associated with higher odds of clinical improvement by day 4 (OR = 8.11; 95% CI 3.18—23.28; p < 0.001), faster resolution of cough and chest pain, and between-group differences in selected laboratory parameters on day 7. Serum interleukin-6 (IL-6) levels on day 7 did not differ significantly between groups. No adverse reactions or side effects were reported in children receiving combination therapy with Viferon®. Conclusions : Inclusion of Viferon® in combination therapy for community-acquired pneumonia in children was associated with faster regression of clinical symptoms and favorable changes in selected laboratory parameters, with no adverse reactions related to therapy recorded in the study.

  • Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan within one international nonproprietary name

    by O.G. Pyaterkina, O.A. Karpova, G.R. Begieva, I.I. Zakirov, D.T. Shayapova, C.A. Bagauova

    Background. Due to the widespread use of targeted therapy drugs with various trade names in the treatment of cystic fibrosis, there is a need for a clinical evaluation of the results of treatment with these drugs and their tolerability and safety within the framework of routine clinical practice. Objective. The aim of the study was to present the experience of the Republic of Tatarstan in the etiopathogenetic therapy of ivacaftor + tezacaftor + elexacaftor and ivacaftor with a change of trade name within the same international nonproprietary name in pediatric patients diagnosed with cystic fibrosis, to demonstrate the clinical efficacy of this drug and its safety Conclusion. During 2025, 80 patients received etiopathogenetic therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor, including 12 children under 6 years of age, 19 aged 6 to 12 years, and 46 patients aged 12 to 18 years. The average age of patients at the start of therapy was 7.5 years. Patients with the pulmonary-intestinal form of the disease (E 84.8) prevailed – 78.3%, with a predominantly pulmonary form (E 84.0) – 21.7%. Prior to the initiation of targeted therapy and when changing the drug to a triple fixed dose combination, a comprehensive assessment of the functional capabilities of the child's body was carried out within the framework of one international nonproprietary name. Monitoring of the safety and effectiveness of treatment was carried out 14 days after the start of therapy, 1 month after, 3 months after, 6 months after, and 12 months after. Against the background of the three-component targeted therapy, patients showed an improvement in respiratory function (FEV1 and FVC), positive weight and height dynamics. When changing the drug within the same international nonproprietary name , the indicators of the function of external respiration remained at the achieved level. During the 6 months of follow-up, there were no exacerbations of cystic fibrosis that required hospitalization.


  • Open Access

    Nutrition and vitamins and minerals availability in children with recurrent respiratory infections in Kazan

    by A. I. Safina, G. Sh. Mansurova, I. I. Zakirov

    Introduction. Recurrent respiratory infections in childhood are a pressing medical and social problem. Nutrition is important for the functioning and development of the child’s immune system.Aim. To assess the diet and provision of children with recurrent respiratory infections with vitamins (A, E, D, C, B6, B12, folic acid) and minerals (Zn, Fe, Mg, Ca, P).Materials and methods. The study included 65 children aged 3 to 8 years, including 50 children with recurrent respiratory infections, 15 children – the control group.Results. The study among children with recurrent respiratory infections aged 3–8 years revealed a high frequency of deficiency of vitamins D (69%), A (40%), E (35%) and minerals Zn (70%) and Fe (44%). Moreover, the deficiency of vitamins D, A and Zn was most pronounced in children of the main group, compared with the control group (p < 0.05). The results of the survey of parents showed that children with recurrent respiratory infections often (82%) have a low and selective appetite. When assessing the actual nutrition in the structure of the diet, a low frequency of consumption of fish, meat and dairy products, vegetables was noted. Most children of the main group had violations in the diet, such as lack of breakfast, excess carbohydrates and fast food.Conclusion. The dietary features we have established can negatively affect the vitamin and mineral status of children with recurrent respiratory infections. According to the results of the study of the levels of vitamins and minerals in children with recurrent respiratory diseases, the most frequent violations were found for zinc, vitamin D, A and iron.

  • Open Access

    Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan

    by O. G. Pyaterkina, O. A. Karpova, G. R. Begieva, I. R. Zinnatullin, I. I. Zakirov

    In connection with the introduction of targeted therapy for cystic fibrosis (CF) into clinical practice, there is a need to study the clinical effectiveness of these drugs and to record their possible side effects in children.The aim was to present the regional experience of the Republic of Tatarstan in the use of etiopathogenetic therapy (ivacaftor + tezacaftor + elexacaftor) in 41 children diagnosed with CF.Methods. Before initiation of triple therapy, a comprehensive assessment of body functions was carried out. Monitoring of safety and effectiveness was carried out at 14 days, 1 month, 3 months, 6 months, and 12 months after from the start of therapy.Results. In the first 2 weeks from the start of therapy, 10 (27%) patients reported mild side effects in the form of increased cough, sputum, and rhinorrhea, 2 (5,4%) patients had skin rashes, and 3 (8,1%) patients had elevated blood aminotransferases. One child developed encephalopathy due to arterial hypertension several months after starting therapy.Conclusion. Monitoring of the safety of the therapy over 12 months in children with CF showed a satisfactory profile. The therapy was associated with an improvement in the body functions, nutritional status, and quality of life.


  • Open Access

    Supply of vitamins (A, E, D, C, B6, B12) and mineral substances (ZN, FE, MG, CA, P) for children with recurrent respiratory infections and deficiency correction of their deficiency as a possibility to prevent frequent respiratory infections

    by A. I. Safina, I. I. Zakirov, G. Sh. Mansurova, N. Z. Yusupova, V. A. Iskandirova

    Introduction. Recurrent respiratory infections in children are a pressing problem in pediatrics. To maintain and function the immune system in children, their provision of vitamins and minerals is important.Purpose. To assess the provision of children with recurrent respiratory infections with vitamins (A, E, D, C, B6, B12, folic acid) and minerals (Zn, Fe, Mg, Ca, P) and to correct their deficiency with a vitamin-mineral complex.Materials and methods. The study was conducted on 65 children aged 3 to 8 years in 2 groups of children: group 1, children with RID, n = 50; group 2 – control, n = 15). An outpatient examination, a parent survey and a blood test for vitamins (A, E, D, C, B6, B12, folic acid) and minerals (Zn, Fe, Mg, total Ca, Ca++, P) were carried out. 30 children with RID were prescribed the vitamin and mineral complex, 1 tablet 2 times a day, with an assessment of vitamin and mineral sufficiency and the frequency of respiratory infections after the end of the dose.Results. In all examined children, both in the main and control groups, the most common were deficiencies of fat-soluble vitamins D (69%), A (40%), E (35%) and the minerals Zn (70%) and Fe (44%). In children with RID, deficiency of vitamins D, A and Zn was more common than in the control group (p < 0.05), in 96% of cases it was combined, more often in the form of a combined deficiency of fat-soluble vitamins D, A, E and minerals Zn, Fe (66% of cases). Taking vitamin-mineral complex in the 2nd prophylactic dose for 1 month contributed to an improvement in vitamin and mineral sufficiency and a decrease in respiratory morbidity in the next 2 months after stopping the drug.Conclusion. Vitamin-mineral complex can be successfully used to maintain vitamin and mineral levels and reduce respiratory morbidity in children with recurrent respiratory infections.

  • Acute kidney injury as the onset of cystic fibrosis in a child of 1 year of age

    by A. I. Safina, T. V. Mikhailova, I. I. Zakirov, I. M. Suleimanova

    Early diagnosis of the cystic fibrosis remains an urgent problem, despite ongoing nationwide neonatal screening. The uniqueness of the presented clinical case lies in the atypical onset of cystic fibrosis in a young child with clinical manifestations of acute kidney injury. The suddenly developed severe general condition in a child was due to manifestations of acute renal injury of the third stage (severe lethargy, anuria for 14 hours, an increase in blood creatinine to 121 µmol/L, a decrease in glomerular filtration rate to 17.4 mL/min), decompensated metabolic alkalosis with hypokalemia, hyponatremia, hypocalcemia (pH 7.6, K+ 2.6 mmol/L, Na+ 118 mmol/L, Ca2+ 0.96 mmol/L, HCO3 – 35.5 mmol/L). The observed disturbances in acid-base status and electrolyte metabolism were manifestations of the pseudo-Bartter syndrome. For the prevention of acute kidney injury in a patient with cystic fibrosis, timely electrolyte and fluid management is important to prevent the development of pseudo-Bartter’s syndrome, exsicosis and hypovolemia.

  • ORGANIZING PNEUMONIA IN CHILDREN: EPIDEMIOLOGY, ETIOLOGICAL STRUCTURE, CLINICAL AND COMPUTED TOMOGRAPHIC SEMIOTICS, COMORBIDITY, THERAPY

    by N.I. Kolganova, D.Yu. Ovsyannikov, M.I. Ayrapetyan, S.A. Bulynko, Sh.A. Gitinov, V.V. Gorev, D.A. Zhakota, O.I. Zhdanova, M.A. Zhestkova, I.I. Zakirov, et al.


  • Open Access

    Tactics of expectorant medicine use in pediatric practice

    by I. I. Zakirov, E. V. Generalova, F. F. Rizvanova

    Introduction. Cough is one of the most frequent complaint when contacting a pediatrician. One of the mechanisms of cough development is the formation of viscous difficult-to-separate sputum. Therefore, determining the tactics of using expectorants and choosing the most effective and safe drug is an important part of the pediatrician’s work.Аim. Тo study the tactics of expectorant medicines use in pediatric practice.Materials and methods. The study included 84 patients with acute respiratory viral infections accompanied by cough, including 36 (42.85%) girls and 48 (57.15%) boys. The age of the children ranged from 4 to 7 years and averaged 5.57 ± 0.88 years. The drug of herbal syrups based on ivy extract in the form of syrup was prescribed to children in a dosage of 2.5 ml 4 times a day for 7 days. The effectiveness of the drug was evaluated on a scale of improvement/worsening of cough symptoms. In addition, the frequency of coughing, the ease of sputum discharge and the well-being of patients according to VAS were evaluated. The safety of the drug was assessed by identifying signs of the development of adverse events. Statistical processing of the obtained data was carried out using the SPSS 12.0 program.Results and discussion. After 7 days of the medicine using, a significant decrease in the frequency and severity of cough was recorded, as well as relief of sputum discharge in most children. 84.52% of children had no cough after the first week of therapy. In this regard, their well-being has significantly improved. No adverse events were detected during the use of the drug. Very few herbal medicinal products are manufactured for young children, whereas it is herbal therapy that is the most suitable for use at this age. The study of the effects of herbal medicinal products containing ivy leaf extracts approved for use in children from birth showed promising results.Conclusions. The use of the drug of herbal syrups based on ivy extract in preschool children contributes to a significant reduction in the frequency of cough, relief of sputum discharge and improvement of patients’ well-being. The drug is safe – there were no adverse events during its use.

  • Open Access

    Experience of organizing a children’s COVID and provisory hospital on the basis of children’s city hospital No1 in Kazan

    by V. S. Filatov, I. Ya. Lutfullin, A. I. Safina, M. V. Potapova, O. V. Sharipova, M. A. Daminova, I. I. Zakirov, E. V. Volyanyuk, Е. А. Кузьмина, G. F. Gimadutdinova, et al.

    Introduction. The pandemic of coronavirus infection, declared by WHO on March 11, 2020, in the first months practically did not affect the inhabitants of the Russian Federation, which gave the healthcare system an advantage in the form of a temporary lag to prepare for the mass admission of patients to infectious diseases hospitals.Aim. To disclose the issues of organization and operation of a children’s covid and provisional hospital on the basis of a separate medical institution as a single whole entity, which functioned for 495 days from 04/08/2020 to 08/15/2021 on the basis of the City Children’s Hospital №1 of Kazan.Materials and methods. Descriptive statistics of 1554 cases of coronavirus infection COVID-19 in childhood are given, topical aspects of epidemiology, the clinical course of the disease and the significance of comorbid pathology are discussed.Results. In the process of work, we noted three rises in the incidence: in June 2020, December 2020 and July 2021. In 61.2% (n = 951) of cases, intrafamily infection was noted, in 11.9% (n = 185) – infection in children’s groups, in 26.9% (n = 418) of cases the source of infection was not identified. The course of the disease was moderate in 74.3% of patients (1154 children), severe in 4.1% (64 children) and mild in 21.6% (336 children), whose hospitalization was justified by social reasons or serious comorbid pathology. The incidence of pneumonia was 21.4% (333 children). COVID-19 was diagnosed in 47 newborns, which proceeded in a severe (2.1% of cases, n = 1), moderate (66% of cases, n = 31) and mild (31.9% of cases, n = 15) form.Conclusions. City Children’s Hospital № 1 of Kazan, transformed into a temporary children’s covid and provisional hospital, provided medical care to 7831 children, including 1554 patients with COVID-19 in the period from 04/08/2020 to 08/15/2021. This organizational decision made it possible to provide those in need with the necessary medical care, organize the routing of patients, and create a reserve of beds.

  • Open Access

    To the 100th anniversary of postgraduate pediatric education at the Kazan State Medical Academy (historical essay)

    by A. I. Safina, L. Z. Safina, M. A. Daminova, I. Ja. Lutfullin, I. I. Zakirov, T. V. Mikhailova, O. A. Stepanova, Е. V. Volyanyuk, N. L. Rybkina, E. G. Ignashina, et al.

    К 100-летию постдипломного образования педиатров в Казанской государственной медицинской академии (исторический очерк)